Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

466
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
466
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

788
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
788
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-coding RNAs in Parkinson's Disease: Pathogenesis, Exosomes, and Therapeutic Horizons.

Cellular and molecular neurobiology·2025
Same author

Modulating PAK1: Accessory Proteins as Promising Therapeutic Targets.

Biomolecules·2025
Same author

Modulation of hormonal, metabolic, inflammatory and oxidative stress biomarkers in women with polycystic ovary syndrome following combined (resistant and endurance) training: a randomized controlled trail.

BMC endocrine disorders·2025
Same author

Berberine and Lung Cancer: From Pure Form to Its Nanoformulations.

Asia-Pacific journal of clinical oncology·2024
Same author

Melatonin for gastric cancer treatment: where do we stand?

Naunyn-Schmiedeberg's archives of pharmacology·2024
Same author

Insight into the cardioprotective effects of melatonin: shining a spotlight on intercellular Sirt signaling communication.

Molecular and cellular biochemistry·2024

Related Experiment Video

Updated: Jan 4, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K

Melatonin: A promising agent targeting leukemia.

Rana Shafabakhsh1, Hamed Mirzaei1, Zatollah Asemi1

  • 1Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.

Journal of Cellular Biochemistry
|November 13, 2019
PubMed
Summary

Melatonin, a natural compound, shows promise for treating leukemia by targeting cancer cells and protecting normal bone marrow. Further research into its molecular mechanisms could lead to new leukemia therapies.

Keywords:
antiangiogenesis propertyleukemiamelatonin

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

502
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

502
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Leukemia is a global public health concern with limited treatment options causing severe side effects and drug resistance.
  • Current leukemia treatments often lack specificity, leading to damage of normal cells and development of resistance.
  • Novel therapeutic strategies are essential for effective leukemia treatment.

Purpose of the Study:

  • To summarize the molecular targets of melatonin in leukemia models.
  • To explore the potential of melatonin as a novel therapeutic agent for leukemia.
  • To highlight melatonin's anticancer properties and protective effects on normal cells.

Main Methods:

  • Literature review of studies on melatonin's effects in various diseases and cancers.
  • Analysis of research investigating melatonin's anticancer properties like pro-oxidation and apoptosis induction.
  • Examination of studies on melatonin's impact on normal bone marrow cells and physiological reactions.

Main Results:

  • Melatonin exhibits anticancer features including pro-oxidation, apoptosis induction, and inhibition of metastasis and invasion.
  • Altered melatonin levels are observed in various cancers, including hematopoetical cancers.
  • Melatonin demonstrates protective effects on normal bone marrow cells, suggesting its potential in leukemia therapy.

Conclusions:

  • Melatonin's diverse anticancer properties and protective effects on normal cells position it as a promising candidate for novel leukemia therapies.
  • Understanding melatonin's molecular targets in leukemia is crucial for developing effective treatment strategies.
  • Further investigation into melatonin's therapeutic potential could overcome current limitations in leukemia treatment.